The startup operates a pharmaceutical firm focused on plant-based therapeutics, providing precise hemp and cannabis analysis for potency, contaminant testing, and stability data generation. This enables researchers to develop effective treatments for post-traumatic stress disorder, chronic pain, and other conditions affecting patients and veterans.
Funding
$28.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients experience unmet medical needs related to pain, neurological, and inflammatory conditions that are not adequately addressed by existing treatments. Current pharmaceutical options may be addictive or have limited efficacy, leaving patients seeking alternative therapeutic solutions.
Solution
BRC Therapeutics is a pharmaceutical company focused on developing proprietary, multimodal cannabinoid therapeutics designed to address these unmet medical needs. Their medicines combine cannabinoids at defined ratios to maximize safety and efficacy. BRC has a pipeline of treatments addressing pain, neurological, and inflammatory conditions, with two investigational products currently in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). The company is registered with the Drug Enforcement Administration (DEA) and is focused on providing safe, non-addictive medicines to improve patients' quality of life.
Target Audience
The primary target audience includes patients suffering from pain, neurological disorders, and inflammatory conditions, as well as physicians seeking alternative, non-addictive treatment options for their patients.
Features
- Proprietary poly-cannabinoid formulations with titratable standardized dosages
- Multimodal therapeutics combining cannabinoids at defined ratios
- cGMP manufacturing processes to ensure product quality and consistency
- Clinical trials underway for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA)
- DEA compliance for botanically derived cannabinoids (phytocannabinoids)